Yüklüyor......
Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden
Background. Despite recognized risks associated with hyperphosphataemia in patients with chronic kidney disease (CKD) Stage 5 on dialysis, the achievement of target levels of serum phosphate is poor. It is likely that this is partly due to poor adherence by patients to their phosphate-binder treatme...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2008
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2568007/ https://ncbi.nlm.nih.gov/pubmed/18577536 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfn310 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|